Analyst Research Report Snapshot

Title:

MOSL: PERSISTENT SYSTEMS (Buy) -Significant operating beat led by IP revenues - guidance of a stronger 2H

Price:

$104.00

Provider:

Motilal Oswal Securities Ltd.

Date:

22 Oct 2013

Pages:

10

Type:

AcrobatPDF

Companies referenced:

PERS.NS

Available for Immediate Download
Summary:

Persistent Systems (PSYS IN, Mkt Cap USD0.5b, CMP INR739, Buy) Ashish Chopra (Ashish.Chopra@MotilalOswal.com) / Siddharth Vora (Siddharth.Vora@MotilalOswal.com) Persistent Systems’ (PSYS) 2QFY14 revenue at USD68.45m grew 8.6% QoQ, above our estimate of USD66.5m (+5.5% QoQ). EBITDA margin during the quarter was up +480bp QoQ to 26%, v/s our estimate of 22.4%. Better-than-expected growth in IP-led revenue drove beat in EBITDA. PAT grew 6.5% QoQ to INR608m (significant beat to our estimate of INR488.6m) and was lower despite significant beat in revenue and margins, due to a forex loss of INR100m, compared to a gain of INR183.5m in the last quarter. Growth in Product Engineering and Platform was 3.5% QoQ to USD55.38m, in line with our estimate of USD55.65m. Beat in overall revenues was driven by IP-led revenue, which grew 37.4% QoQ to USD13.1m, well above our estimate of USD10.8m. HPCA contributed ~USD1m to revenue and the remaining growth was organic, led by location-based IP. Company’s guidance of sustaining 24-25% EBITDA margin over the longer term is a positive. Also, growth in IP-led segment should continue to remain strong as: [1] full quarter revenue from HPCA kicks in, [2] the location-based deal signed in South Africa ramps up and [3] 4QFY14 will be a seasonally strong one for the segment for royalty revenue from top clients. We upgrade USD revenue estimates for FY14E/FY15E by 1.1%/1.4%, following a strong performance in 2QFY14 and healthy outlook for the remainder of the year. Our EBITDA margin estimates for FY14E/FY15E are revised upwards by 110bp/180bp. Thus, our EPS is raised by 6.4%/10.8% for FY14E/FY15E to INR61.3/74. We believe PSYS is one of the few choices in tier-II IT space, with the potential to grow revenue in the range of or above 20%, given its focus on the fast-growing SMAC business, multi-year relationships with marquee clientele in the Infrastructure vertical and unlikely obsolescence in the space where it operates. We expect PSYS to post USD revenue at a CAGR of 18% over FY13-15E and EPS at a CAGR of 25.6% during the period. Our target price of INR820 discounts FY15E EPS by 11x. Maintain Buy.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.